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Abstract: Psoriasis is a chronic inﬂ  ammatory, immune-mediated skin disorder that affects 
1.5–1.8 million people in Italy. The most common form of the disease is chronic plaque pso-
riasis, affecting about 90% of psoriasis patients, with about 20%–30% of them suffering from 
a moderate or severe condition. Little information is available about the economic impact of 
psoriasis in European countries. The primary objective of this study was to perform a cost-of-
illness analysis of patients with moderate and severe plaque psoriasis in Italy. Therefore, direct, 
indirect costs, and intangible costs (quality of life – QoL) were assessed. In this national, multi-
center, prospective, 3-month cost-of-illness study of moderate and severe plaque psoriasis, 
direct and indirect costs were assessed from the patient, third-party payer (National Health 
Service, NHS), and societal perspectives. From November 2003 to October 2004 consecutive 
patients were enrolled over a 1-year period, in order to minimize seasonal ﬂ  uctuations in disease 
severity. 150 patients enrolled in 6 investigational sites in Italy, completed the study, and were 
eligible to be analyzed according to the study protocol. Intangible costs (QoL) were measured 
using SF36 and DLQI questionnaires. The mean total cost for psoriasis (average Psoriasis Area 
Severity Index [PASI] score 21.4), including direct and indirect items, was  8,371.61 per patient 
per year. The mean cost for patients with moderate disease (PASI  20) was  5,226.04, while 
the mean cost for patients with more severe disease (PASI  20) was  11,434.40 per year. 
Disease heavily affected QoL measured using SF36, and the impairment was greater in patients 
affected by a more severe form of disease. Moderate and severe plaque psoriasis is associated 
with extremely high costs, which are related to disease severity. Data from this study show that 
the more severe plaque psoriasis, the higher the direct and indirect costs for its management. 
Direct costs are higher than indirect costs; hospitalization represents the most signiﬁ  cant item, 
accounting for 30% of the total expenses. QoL in moderate and severe plaque psoriasis is low 
compared with the population at large, conﬁ  rming the high impact of plaque psoriasis on QoL. 
The relatively high average annual costs per patient point to the need for a more efﬁ  cient and 
long-term control of psoriasis.
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Introduction
Psoriasis is a chronic inﬂ  ammatory skin disorder that affects approximately 1–3% 
of the world population and almost 2% of the European population, about 1.5–1.8 
million people in Italy (Plunkett et al 1998; Sterry et al 2004; Naldi et al 2004). The 
most common form of the disease is chronic plaque psoriasis, an immune-mediated 
disorder that affects about 90% of psoriasis patients, with about 20%–30% of them 
having a moderate or severe condition.Its high prevalence and chronic nature have 
profound effects on the patients’ quality of life.
Psoriasis severity is deﬁ  ned by the extent of body surface involved, the lesion 
characteristics, or the impact of the disease on quality of life (QoL) (Finlay et al 2005). 
In general, patients with a body-surface involvement higher than 10%, or a Psoriasis 
Area Severity Index (PASI) 10, or a Dermatology Life Quality Index (DLQI) 10 Therapeutics and Clinical Risk Management 2008:4(2) 560
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are considered appropriate candidates for systemic therapy 
(Kirby et al 2000; Shikiar et al 2003). However, even patients 
with less extensive disease, but localized to certain body areas 
(hands, face, genitalia), may need systemic therapy or pho-
totherapy instead of topical therapy (Rapp et al 1999). Pso-
riasis can be associated with other diseases (Del Giglio et al 
2007). The most common co-morbidities include psoriatic 
arthritis and anxiety/depression disorders (Gisondi et al 2005; 
Kimball et al 2005). Psoriatic arthritis affects approximately 
10%–15% of psoriasis patients (Parisier et al 2007). More 
recently, an association has also been reported between pso-
riasis and metabolic disorders, including abdominal obesity, 
atherogenic dyslipidemia, hypertension, and diabetes, which 
produces an unfavorable cardiovascular risk proﬁ  le (Gelfand 
et al 2006; Neimann et al 2006; Malerba et al 2006; Shapiro 
et al 2006; Boehncke et al 2007; Gisondi et al 2007). Major 
factors that may contribute to this increased cardiovascular 
risk also include cigarette smoking, physical inactivity, 
hyperhomocysteinemia, and psychological stress, all of 
which have an higher prevalence among psoriasis patients 
(Malerba et al 2006). The cardiovascular risk factors involved 
in the metabolic syndrome are more strongly associated with 
severe psoriasis than with mild psoriasis.
A higher risk for arterial and venous thrombosis (Mallbris 
et al 2004), and a 3-fold increased risk of myocardial infarc-
tion have been reported especially in young patients with 
severe psoriasis (Gelfand et al 2006). The presence of these 
co-morbidities should be carefully evaluated in patients with 
psoriasis, when selecting the most appropriate therapy. As a 
matter of fact, many traditional systemic therapies such as CsA 
and MTX may negatively affect cardiovascular risk factors, 
especially in the long term (Gisondi et al 2007). In addition, 
patients with cardiovascular diseases are often under treatment 
with several drugs, and drug interactions must also be taken 
into account when selecting an antipsoriatic treatment. Because 
the disease is usually persistent and progressive, patients with 
a diagnosis of psoriasis usually need lifelong care, which also 
means a lifetime of expenses. From an economic perspective, 
there are many inﬂ  uencing factors on the costs of psoriasis to 
be taken into account, such as the increasing costs relating 
to prescription drugs, over-the-counter (OTC) and self-care 
products, hospitalizations, productivity loss due to absence 
from work for sick leave, and time spent by patients in medical 
consultations, treatments, or diagnostic procedures (Braathen 
et al 2001; Dehkharghani et al 2003).
It has recently been demonstrated that psoriasis has a 
relevant impact, and some cost implications, on the patients’ 
family members and/or caregivers (Eghlileb et al 2007). 
Since little information about the economic impact of psoriasis 
in European countries is available (Sohn et al 2006), we 
conducted a study to evaluate the direct and indirect costs 
related to moderate and severe plaque psoriasis in an Italian 
population and to assess the correlation of cost with the 
different degrees of severity of the disease and to measure 
the impairment in QoL.
Patients and methods
Design
We carried out a 3-month, national, multicenter, observa-
tional, prospective cost-of-illness study of moderate and 
severe plaque psoriasis. Direct, indirect costs, and intangible 
costs (QoL) were considered from the patient, third-party 
payer (National Health Service, NHS – Servizio Sanitario 
Nazionale, SSN) and societal perspectives. QoL data were 
also collected. The study design included 2 medical examina-
tions, at baseline and after 3 months.
Recruitment
From November 2003 through October 2004, patients with 
moderate and severe psoriasis attending 6 departments of 
dermatology were invited to participate in the study. The 
involved centers were: Clinica di Dermatologia, Policlinico 
Tor Vergata, Roma; Clinica Dermatologica Università degli 
Studi de l’Aquila; Istituto Ortopedico Galeazzi, Dipartimento 
di Scienze Cliniche Luigi Sacco, Milano; Clinica di Derma-
tologia Azienda U.S.L.2, Lucca, Monte San Quirico; Presidio 
ospedaliero Vito Fazi U.O. di Dermatologia, Lecce.
Consecutive patient enrolments occurred over 1 year. In 
order to minimize seasonal ﬂ  uctuations in disease severity 
the study period was divided in 4 consecutive periods (Q1: 
Nov 2003/Jan 2004; Q2: Feb/Apr2004; Q3: May/Jul 2004; 
Q4: Aug/Oct 2004).
Inclusion criteria
Patients aged 18 with moderate or severe plaque psoriasis were 
included in the study. Disease severity was classiﬁ  ed as 12 
according to the PASI. Disease severity was scored as moderate 
when PASI was 12–20 and severe when PASI score was 20. 
PASI score is the most accepted and widely used measure to assess 
disease severity and improvement in clinical trials and clinical 
practice. The study was approved by the local ethical committees 
and the Declaration of Helsinki protocols were followed. Written 
informed consent was obtained from all participants.
Data collection
Patients were invited to participate in the study at the time of 
their dermatological examination. Data on resource utilization Therapeutics and Clinical Risk Management 2008:4(2) 561
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between Visit 1 and Visit 2 were collected using a 2-part 
semi-structured questionnaire: the “dermatologist question-
naire” and the “patient questionnaire”. At the dermatological 
examination (Visit 1), the evaluating physician completed the 
“dermatologist questionnaire”, containing data on medical 
history, physical examination, and any concomitant drug both 
topic and systemic. The patient was given a self-administered 
questionnaire (“patient questionnaire”), to be completed on 
the ﬁ  rst and second examinations. The “patient questionnaire” 
registered data on socio-demographic characteristics and QoL, 
by means of the 2 self-administered questionnaires, DLQI and 
SF-36. During the ﬁ  rst examination (Visit 1), patients were 
asked to keep all drug packs (including cream tubes) that 
would be used in the next quarter, in order to verify real drug 
consumption. Patients were evaluated again after 3 months 
(±15 days) at Visit 2. At Visit 2, the following data were 
collected: results of physical and laboratory examinations as 
well as diagnostic procedures, the number and time of hospi-
talizations, concomitant drugs, non-conventional treatments, 
concurrent visits by dermatologists and other medical special-
ists, and working days lost in the previous quarter.
Costing
The direct, indirect, and intangible costs (QoL) of the present 
study were assessed as follows:
Direct costs
Medical costs related to: a) hospitalization, b) day-hospital 
admissions, c) specialist medical examinations, d) laboratory 
tests and instrumental investigations, e) phototherapy, f) 
drug therapies. The costs for hospitalization and day-hospital 
admission were evaluated on the basis of the national DRG 
system available from the Italian Ministry of Health (Health 
Ministry 2006a). Specialist medical examinations, laboratory 
tests, diagnostic procedures, and phototherapy sessions were 
based on the “2006 National Tariff Nomenclator” (Health 
Ministry 2006b). Health care services provided by the private 
sector and other private costs were evaluated based on the 
actual expenses incurred in by the patients. All pharmacologi-
cal therapies (topical, systemic) were considered in the ques-
tionnaire. Non conventional treatments were also assessed. 
The annual treatment pattern was obtained through the assess-
ment of the total drug consumption over a 1-year period, in 
order to minimize possible seasonal ﬂ  uctuations in disease 
severity. To assess the costs of prescribed pharmacological 
therapies, units of consumed resources were multiplied by the 
prices reported in the ofﬁ  cial Italian price list (Informatore 
Farmaceutico 2007), taking into consideration the dosage 
and duration of the treatment. The costs of non-prescription 
topical medications and non-conventional treatments were 
determined by averaging the costs of the most representa-
tive drugs recorded in the patients’ notebooks, based on the 
ofﬁ  cial retail price list. All costs are expressed in Euros and 
were updated to 2006 values according to ofﬁ  cial inﬂ  ation 
rates (Italian inﬂ  ation rates 2007).
Indirect costs
The human capital approach was used to estimate the pro-
ductivity loss due to plaque psoriasis. Travel costs were not 
collected. Indirect costs included the value of lost production 
due to leaving work earlier than usual in the day, sick leave 
and loss of leisure time for non-employees during the time 
of the study. Patients’ time off work (lost working days, per-
manent reduction, or loss of work activities) was measured in 
terms of salary evaluation, with the assumption that income 
reﬂ  ects productivity. The monetary value of 1 lost working 
day for patients was calculated as  98.44, equal to the gross 
domestic product (GDP) per capita/day (Banca d’Italia 2006). 
National income data were subsequently updated to 2006 
according to ofﬁ  cial inﬂ  ation rates and represented a mean 
value for all of Italy.
The analysis was done from the society and NHS 
perspectives.
Intangible costs
In order to assess the functional status and QoL in their broad 
aspects, patients were asked to ﬁ  ll in the SF-36 and the DLQI 
questionnaires.
The SF-36 is a multi-purpose, short-form health survey 
with 36 questions. It yields an 8-scale proﬁ  le of functional 
health and well-being scores, as well as psychometrically-
based physical and mental health summary measures, and a 
preference-based health utility index. It is a generic measure, 
as opposed to one that targets a speciﬁ  c age, disease, or treat-
ment group (Apolone et al 1997).
The DLQI is a dermatology-speciﬁ  c measure which 
consists of 10 questions related to patient’s symptoms and 
feeling, daily activities, leisure, work or school, personal 
relationship and treatment over the previous 1 week. The 
total DLQI ranges from 0 (no impairment of QoL) to 30 
(maximum impairment of QoL) (Finlay et al 1994).
Statistics
First exploratory data analyses were performed in order 
to provide all the frequencies on all variables of the ques-
tionnaire. These descriptive analyses included distribution Therapeutics and Clinical Risk Management 2008:4(2) 562
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Table 2 Treatment pattern at Visit 1 by disease severity
Moderate PASI  20 Severe PASI  20 Total P value*
%N %N %N
49.3 (%) 74 50.7 (%) 76 100 (%) 150
Drug therapy
Topic 68.9 (%) 51 75.0 (%) 57 72.0 (%) 108
Systemic 23.0 (%) 17 15.5 (%) 11 18.7 (%) 28 0.005
Phototherapy 35.1 (%) 26 80.3 (%) 61 58.0 (%) 87
Adoption of combination 
vs monotherapy
Combination 37.8 (%) 28 65.8 (%) 50 52.0 (%) 78
Non-conventional 
treatments
Balneotherapy 13.5 (%) 10 6.6 (%) 5 10.0 (%) 15
Homeopathy 13.5 (%) 10 19.7 (%) 15 16.7 (%) 25
Bach’s ﬂ  owers 2.7 (%) 2 2.6 (%) 2 2.7 (%) 4 0.377
Other therapies 4.1 (%) 3 6.6 (%) 5 5.3 (%) 8
*Moderate vs Severe.
Abbreviation: PASI, Psoriasis Area Severity Index.
Table 1 Demographic and disease characteristics in moderate and severe psoriasis
Moderate PASI  20 Severe PASI  20 Total P value∗
N or % N or SD N or % N or SD N or % N or SD
N 49.3% 74 50.7% 76 100.0% 150
Mean age in years 49.1 15.2 47.4 13.8 48.3 14.5 0.478
Sex (male) 64.9%  48 67.1%  51 66.0% 99
Mean age at ﬁ  rst diagnosis (years) 30.4 15.2 28.7 15.5 29.5 15.3 0.505
Mean duration of disease (years) 18.8 12.9 18.5 11.7 18.7 12.3 0.901
PASI
   Mean  PASI 14.7 2.2 28.0 6.4 21.4 8.2 0.000000
BSA
   Mean  BSA 31.4 11.4 48.0 13.7 39.8 15.1 0.000000
DLQI
    10
    10
   Mean  DLQI
70.3% 52 59.2% 45 64.7% 97
29.7% 22 40.8% 31 35.3% 53 0.157
8.2 5.7 9.6 6.3 8.9 6.0 0.153
Occupation
   Employed
   Retired,  unemployed
51.4% 38 55.3% 42 53.3% 80
48.6% 36 44.7% 34 46.7% 70 0.631
*Moderate vs Severe.
Abbreviations: PASI, Psoriasis Area Severity Index; BSA, body surface area; DLQI, Dermatology Life Quality Index.Therapeutics and Clinical Risk Management 2008:4(2) 563
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patterns (ranges, means, medians, skewness), missing values, 
and outliers on quantitative variables. The statistical methods 
included: analysis of variance (ANOVA) taking the center 
effect into account, applied to continuous variables: age at 
ﬁ  rst diagnosis and mean duration of disease; and Chi-square 
test for categorical variables such as employment status, 
marital status, gender, stratiﬁ  ed by center.
Results
Study population
Table 1 shows the main socio-demographic and disease 
characteristics. The mean age of the 150 patients examined, 
99 males (66.0%) and 51 females (34.0%), was 48.3 years. 
The majority (53.3%) were employed, while 46.7% were 
unemployed or retired.
The mean age at ﬁ  rst diagnosis was 29.5 years (30.4 years 
for patients with moderate psoriasis, 28.7 years for patients 
with severe psoriasis). The mean time of disease duration was 
18.7 years. Disease severity, as assessed by PASI score, was 
moderate in 49.3% of patients (64.9% males) and severe in 
50.7% of patients (67.1% males).
Patients were also asked to complete the DLQI and SF-36 
questionnaires. The DLQI score at the baseline examination 
was 10 for 53 patients (35.3%). DLQI scores correlated 
to the patients’ classiﬁ  cation on the basis of PASI, showing 
a worsening in the patients’ conditions, since 29.7% of the 
patients with moderate psoriasis and 40.8% of the patients 
with severe psoriasis had a DLQI higher than 10. Average 
DLQI score was 8.2 for patients with moderate psoriasis, 
and 9.6 for patients with severe psoriasis. Body surface area 
(BSA) score also conﬁ  rmed the classiﬁ  cation of disease 
severity based on the PASI parameters.
Treatment pattern
Treatment patterns at baseline (Visit 1) are shown in Table 2. 
At the time of recruitment, the majority of patients received 
topical treatment (72.0%) and phototherapy (58.0%) or 
multiple therapy (52%). At 3 months, the number of patients 
receiving topical treatment increased (86.0%), and also the 
number of hospitalizations and medical examinations is 
signiﬁ  cantly high, involving 66 (44.0%) and 136 (90.7%) 
patients respectively (Table 3).
Resource utilization and absence 
from work
The consumption of medical services and medications at 
Visit 1 and in following 3 months is shown in Table 4 and 
Figure 1. The mean total cost (direct and indirect) per patient 
was  8,371.61 per year.
Direct costs accounted for 68% of the total estimated 
disease costs for moderate and severe plaque psoriasis. The 
most signiﬁ  cant direct costs pertained to hospitalization 
(44%) followed by laboratory examinations (28%), while 
costs due to topical or systemic therapy only accounted for 
5% and 14%. Signiﬁ  cantly, while the majority of patients 
at Visit 2 were using a topical therapy (129), this represents 
only 4% of the total cost of medical and pharmacological 
therapy (Tables 3 and 4). On the other hand, hospitalization 
costs at Visit 2 account for 30% of total costs, but they are 
Table 3 Treatment patterns at Visit 2 by disease severity
 Moderate  PASI   20  Severe PASI  20  Total    P value∗
 %  N  %  N  %  N 
  49.3  (%)  74  50.7  (%)  76  100 (%)  150
Pharmacological treatment      
Topic  78.4 (%)  58  93.4 (%)  71  86.0 (%)  129  0.228
Systemic  36.5 (%)  27  59.2 (%)  45  48.0 (%)  72 
Phototherapy  35.1 (%)  26  68.4 (%)  52  52.0 (%)  78
Hospitalization  21.6 (%)  16  65.8 (%)  50  44.0 (%)  66  0.003
Medical examinations  83.8 (%)  62  97.4 (%)  74  90.7 (%)  136 
*Moderate vs Severe.
Abbreviation: PASI, Psoriasis Area Severity Index.
Table 4 Direct and indirect costs per year
 Total  Per  patient  %
Direct cost    
Topic  € 44,168.75  € 294.46  4%
Systemic  € 119,597.24  € 797.31  10%
Phototherapy  € 53,768.72  € 358.46  4%
Hospitalization  € 376,535.64  € 2,510.24  30%
Ambulatory visit  € 23,780.92  € 1,578.54  2%
Laboratory examinations  € 235,664.28  € 1,571.10  19%
Subtotal direct cost  € 853,515.55  € 5,690.10  68%
Indirect cost (loss of  € 402,225.84  € 2,681.51  32%
productivity)
Total cost  € 1,255,741.39  € 8,371.61  100%Therapeutics and Clinical Risk Management 2008:4(2) 564
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attributed to less than half of the patients (66), as reported 
in Table 3.
Costs related to loss of productivity amounted to 
2,681.51, accounting for 32% of total costs (Figure 1).
The expenses incurred for psoriasis treatment were sig-
niﬁ  cantly higher in those patients with more severe psoriasis 
(PASI  20) than in patients with moderate plaque psoriasis 
(PASI 20) (PASI 10–20) (Table 5 and Figure 2). While 
the annual costs per patient with moderate plaque psoriasis 
amounted to  5,226.04, the costs per patient with a severe 
condition were  11,434.40. The cost differences between 
moderate and severe psoriasis were predominantly due to 
the higher hospitalization costs, phototherapy, laboratory 
examinations, systemic drugs, and costs related to loss of 
productivity. The most signiﬁ  cant item is hospitalization, 
which represents 30% of the total expenses, with differences 
between patients with moderate psoriasis (25%) and severe 
psoriasis (32%) as shown in Figure 3.
Intangible costs
Figure 4 compares the results of the SF-36 questionnaire 
in the study population with the mean values of the Italian 
general population (Apolone et al 1997). All the measure-
ments performed at Visit 1 are below the mean, thus con-
ﬁ  rming the high impact of plaque psoriasis on the QoL of 
patients. In particular, patients reported worsening for role 
and emotional status (RES), role and physical health (RPH), 
and social activities (SA). Table 6 shows the SF-36 score as 
reported at Visit 1 for each of the health items investigated 
by the SF-36, stratiﬁ  ed by patients’ disease severity. The 
psychological impact recorded the lowest score, while the 
physical components seemed to be less affected, as reported 
in Figure 5.
Discussion
Plaque psoriasis is a very common cutaneous disease which 
may have a profound impact on the affected person’s QoL 
and a substantial economic impact for the patients and the 
health care system. In spite of this, only a few studies have 
been performed so far presenting an overall picture of the 
costs of care for patients with psoriasis. This also applies to 
Italy, where little is known about the epidemiology and the 
economics of psoriasis (Marchetti et al 1998; Galadari et al 
2001). Our national multicenter prospective study on the 
cost of illness of moderate and severe plaque psoriasis in 
Italy was performed according to the bottom-up approach on 
patients stratiﬁ  ed by severity of disease (estimated by PASI 
score). Its results provide descriptive data on the pattern of 
resources used and show that:
Table 5 Direct and indirect costs for disease severity per year
 Moderate    Severe 
 PASI   20  PASI  20
Number of patients  74  76
Avg PASI  14.7  28
Per-patient cost
Direct cost
Topic  € 304.69  € 284.49
Systemic  € 555.46  € 1,032.81
Phototherapy  € 261.50  € 452.86
Hospitalization  € 1,311.40  € 3,677.52
Ambulatory visit  € 159.36  € 157.74
Laboratory examinations  € 1,050.60  € 2,077.89
Subtotal direct cost  € 3,643.02  € 7,683.32
Indirect cost (loss of   € 1,583.02  € 3,751.08
productivity)
Total  € 5,226.04  € 11,434.40
Moderate vs Severe P value 0.005.
Abbreviation: PASI, Psoriasis Area Severity Index.
Figure 1 Direct and indirect costs per year.
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1)  The more severe plaque psoriasis, the higher the direct 
and indirect costs for its management;
2)  Direct costs are higher than indirect costs; hospitalization 
is the most signiﬁ  cant item, accounting for 30% of total 
expenses;
3) QoL in moderate and severe plaque psoriasis is low 
compared with the population at large.
The more severe the psoriasis, the higher the cost of care, 
as reported by Feldman et al (1997), and disease severity is 
related to the cost of treatment, time required for treatment, 
and time lost from work. The social cost of moderate and 
severe plaque psoriasis varies signiﬁ  cantly for each stage of 
the disease, increasing until it more than doubles and goes 
from moderate to severe, according to the PASI score. It has 
Figure 2 Direct and indirect costs for disease severity per year.
Abbreviation: PASI, Psoriasis Area Severity Index.
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recently been demonstrated that psoriasis is also associated 
with unemployment (Horn et al 2007). The annual costs cal-
culated for a patient with moderate plaque psoriasis in Italy 
amounted to  5,226.04, whereas the costs for a patient with 
a severe condition were  11,434.40. The German Cost-of-
Illness study (Finlay et al 1998; Berger et al 2005) found a 
total annual cost per treated patient (direct + indirect costs) 
in a range of  4,985.00–6,709.00, with a mean PASI score 
of 18.2, a reasonably similar value to our study. Moreover, 
the German study highlights a correlation between PASI 
score growth and annual cost per patient, backing up the 
Italian study ﬁ  ndings.
In the present analysis, direct costs are higher than 
indirect costs both for patients with moderate and severe 
plaque psoriasis. It should be pointed out that hospitaliza-
tion represents the most signiﬁ  cant item contributing to 
the total cost, and also among direct costs, as reported in a 
previous cost-of-care study conducted in Italy (Rapp et al 
1999). Indeed, hospitalization represents 30% of the total 
expenses, with differences between patients with moderate 
psoriasis (25%) and severe psoriasis (32%). Using popula-
tion census data and considering the prevalence of psoriasis 
in the Italian population in the year 2006 (Naldi et al 2006), 
the total cost for this disease in our country was estimated to 
be approximately  2,403 million per year on a total national 
health expenditure of  128,914 million (1.8% of the total 
national health expenditure in 2006).
Psoriasis also causes signiﬁ  cant psychosocial problems, 
as the results of the SF-36 questionnaire from this study 
show, which means that improvement in the quality of life 
should be a major issue in economic considerations. These 
results conﬁ  rm the ﬁ  ndings of Sampogna et al (2005): a heavy 
burden on mental health and social functioning was observed, 
comparable to depression. As previously reported, skin 
diseases can substantially diminish QoL, restricting work, 
social, and family relationships (Finlay et al 1998). Patients 
may ﬁ  nd skin diseases more disabling than other diseases that 
are usually considered more serious, as they often feel that 
the disease alters their lives far more adversely than patients 
with basal cell carcinomas, warts, and moles (Koo et al 1996; 
Nevitt et al 1996; Lamberg et al 1997; Finlay 2001).
There are some limitations to this study and the results 
are likely to underestimate total disease costs for various rea-
sons. The ﬁ  rst possible limitation regards the extrapolations 
Figure 4 SF-36: quality of life measurements at visit 1 compared to the mean for the Italian population.
Abbreviations: PASI, Psoriasis Area Severity Index; BP, body pain; GH, general health; MH, mental health; PA, physical activity; RPH, Role-physical; RES, role emotional status; 
SA, social activity; VT, vitality.
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Table 6 SF-36: quality of life measurements at Visit 1* per different 
degrees of severity
 Moderate  Severe
 PASI   20  PASI  20
Physical activity (PA)  80.8  81.4
SD 24.7  23.6
Role-physical (RPH)  70.5  64.5
SD 35.9  40.3
Body pain (BP)  67.4  62.8
SD 28.4  30.1
General health (GH)  59.4  55.6
SD 24.2  21.9
Vitality (VT)  55.9  56.8
SD 21.0  21.8
Social activity (SA)  67.1  65.3
SD 26.5  24.5
Role emotional status (RES)  66.2  56.6
SD 39.9  40.7
Mental health (MH)  60.6  61.3
SD 20.5  22.0
*Measurements are given as a mean (SD).
Abbreviation: PASI, Psoriasis Area Severity Index.Therapeutics and Clinical Risk Management 2008:4(2) 567
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of 3-month expenses to 1 year, as patients’ expenses are not 
strictly related to their current condition (such as a ﬂ  are), but 
are inﬂ  uenced by routinely used items, especially in case of 
moderate or severe disease. Some cost items, such as out-
of-pocket expenses, were not included in the study, since it 
adopted the NHS perspective. The use of the human capital 
approach in calculating indirect costs in the form of overall 
productivity losses can discriminate against people with no 
market value such as the unemployed, retired people, and 
housewives. Overall, this study underestimated some psoria-
sis costs, not included in our protocol, such as co-morbidities 
and reduction of productivity by families and caregivers. 
These expenses might represent an important cost driver on 
the total burden of disease (Sander et al 1993; Feldman et al 
1997; Jenner et al 2002; Sampogna et al 2005; Horn et al 
2007). Further research work is needed to understand the 
reasons for this association.
In this analysis no patient was treated with new biolog-
ics drugs (efalizumab, etanercept, inﬂ  iximab, alefacept) 
for psoriasis; in Italy these therapies were introduced on to 
market only in June 2005, out of our enrollment period. An 
increasing use of innovative treatments in dermatology has 
been noted recently, and with the advent of this new biologics 
drugs psoriasis costs will become even higher. However, the 
prescription of these new costly drugs could be associated 
with a decrease in loss of productivity and a reduction in 
diagnostic procedures and medical care, with a great beneﬁ  t 
for society (Finlay 2001). These investments in innovative 
treatments for psoriasis might also provide future beneﬁ  ts, 
due to the avoidance of recurrent problems, improved com-
pliance, and a better QoL (Berger et al 2005). Adequate 
analysis of outcomes and costs, as performed for biologics 
in current use, should be assessed in terms of incremental 
cost-effectiveness ratio.
In conclusion, moderate and severe plaque psoriasis rep-
resents an important cause of economic burden in Italy, both 
to the society and the NHS. The data presented here show 
that public payers and the individuals themselves afford a 
total cost ranging from  5,226.04 to  11,434.40. The most 
signiﬁ  cant costs were due to hospitalization, followed by 
medical activities and costs for prescription drugs. This study 
provides evidence of the association between psoriasis sever-
ity and cost of illness. This cost-of-illness study provides 
basic data for further decision making, dealing especially 
with economic assessment of innovative therapies for mod-
erate and severe plaque psoriasis. Further data on outcomes 
need to be collected over a long time frame.
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